AOXING PHARMACEUTICAL COMPANY, INC.: 10-Q filed 2015-02-17

Name: AOXING PHARMACEUTICAL COMPANY, INC.: 10-Q filed 2015-02-17
Creator: AOXING PHARMACEUTICAL COMPANY, INC.

What AOXING PHARMACEUTICAL COMPANY, INC. reported in its quarterly report filed 2015-02-17 (fiscal Q2 2015): 34 published measures, 86 facts as tagged in accession 0001096906-15-000192.

This filing

Form: 10-Q (quarterly report)
Filed: 2015-02-17
Fiscal period: fiscal Q2 2015
Accession: 0001096906-15-000192 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AOXING PHARMACEUTICAL COMPANY, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-12-31	40,927,195	USD
At 2014-06-30	38,074,754	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2014-12-31	3,899,088	USD
At 2014-06-30	-2,505,125	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	601,952	USD	92
2014-07-01 to 2014-12-31	599,550	USD	184
2013-10-01 to 2013-12-31	-1,917,469	USD	92
2013-07-01 to 2013-12-31	-4,268,443	USD	184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	3,367,461	USD	184
2013-07-01 to 2013-12-31	-2,817,353	USD	184

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	2,937,622	USD	184
2013-07-01 to 2013-12-31	58,582	USD	184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	-1,451,294	USD	184
2013-07-01 to 2013-12-31	2,813,365	USD	184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	-2,937,622	USD	184
2013-07-01 to 2013-12-31	-58,582	USD	184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2014-12-31	-63,290,383	USD
At 2014-06-30	-63,849,681	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-12-31	28,858,245	USD
At 2014-06-30	26,418,842	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	1,972,517	USD	92
2014-07-01 to 2014-12-31	3,189,246	USD	184
2013-10-01 to 2013-12-31	-662,963	USD	92
2013-07-01 to 2013-12-31	-1,907,924	USD	184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-12-31	11,412,916	USD
At 2014-06-30	10,920,612	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-12-31	31,461,637	USD
At 2014-06-30	34,214,799	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2014-12-31	3,089,127	USD
At 2014-06-30	3,883,198	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2014-12-31	4,526,735	USD
At 2014-06-30	3,890,550	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	2,833,331	USD	92
2014-07-01 to 2014-12-31	4,794,151	USD	184
2013-10-01 to 2013-12-31	2,106,063	USD	92
2013-07-01 to 2013-12-31	4,913,469	USD	184

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2014-12-31	1,882,722	USD
At 2014-06-30	2,195,274	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	4,805,848	USD	92
2014-07-01 to 2014-12-31	7,983,397	USD	184
2013-10-01 to 2013-12-31	1,443,100	USD	92
2013-07-01 to 2013-12-31	3,005,544	USD	184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	95,597	USD	92
2014-07-01 to 2014-12-31	203,147	USD	184
2013-10-01 to 2013-12-31	90,775	USD	92
2013-07-01 to 2013-12-31	268,716	USD	184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-12-31	66,264,932	shares
At 2014-06-30	49,874,822	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-12-31	64,110,230	USD
At 2014-06-30	58,315,446	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2014-12-31	3,012,976	USD
At 2014-06-30	2,979,235	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2014-12-31	2,437,562	USD
At 2014-06-30	-4,008,678	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2014-12-31	3,663,990	USD
At 2014-06-30	2,505,128	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	601,952	USD	92
2014-07-01 to 2014-12-31	599,550	USD	184
2013-10-01 to 2013-12-31	-1,917,469	USD	92
2013-07-01 to 2013-12-31	-4,268,443	USD	184

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	567,168	USD	92
2014-07-01 to 2014-12-31	559,299	USD	184
2013-10-01 to 2013-12-31	-1,825,717	USD	92
2013-07-01 to 2013-12-31	-4,060,703	USD	184

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	574,673	USD	92
2014-07-01 to 2014-12-31	579,922	USD	184
2013-10-01 to 2013-12-31	-1,814,768	USD	92
2013-07-01 to 2013-12-31	-4,029,927	USD	184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	821,008	USD	92
2014-07-01 to 2014-12-31	1,332,495	USD	184
2013-10-01 to 2013-12-31	617,903	USD	92
2013-07-01 to 2013-12-31	1,447,953	USD	184

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2014-10-01 to 2014-12-31	140,802	USD	92
2014-07-01 to 2014-12-31	280,076	USD	184
2013-10-01 to 2013-12-31	138,585	USD	92
2013-07-01 to 2013-12-31	320,011	USD	184

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	547,550	USD	184
2013-07-01 to 2013-12-31	543,056	USD	184

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	209,842	USD	184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	5,816,451	USD	184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	507,188	USD	184
2013-07-01 to 2013-12-31	1,166,186	USD	184

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	230,587	USD	184
2013-07-01 to 2013-12-31	-59,709	USD	184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2014-07-01 to 2014-12-31	-796,885	USD	184
2013-07-01 to 2013-12-31	1,005,119	USD	184

Inspect the source

Entity: AOXING PHARMACEUTICAL COMPANY, INC. / CIK 0001060426
Captured: 2026-09-22 19:38 UTC
SEC response SHA-256: 7853980521379aa80eabc6640ead2d1c15a35f6d0a4bbda971e1bfc382d7827d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001060426.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))